Eletriptan HBr (BioDeep_00000696213)
代谢物信息卡片
Eletriptan hydrobromide
化学式: C22H27BrN2O2S (462.09765020000003)
中文名称: 依来曲普坦氢溴酸盐
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN1CCCC1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4.Br
InChI: /m1./s1
描述信息
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists
C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist
Eletriptan hydrobromide (Eletriptan HBr) is a selective 5-HT1B and 5-HT1D receptor agonist with Ki of 0.92 nM and 3.14 nM, respectively.
同义名列表
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:61176
- KEGGdrug: D01973
- PubChem: 656631
- ChEMBL: CHEMBL1201003
- CAS: 177834-92-3
- medchemexpress: HY-A0010
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yu Kyong Kim, Kwang-Hee Shin, Jeffrey Alderman, Kyung-Sang Yu, In-Jin Jang, SeungHwan Lee. Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects.
Drug design, development and therapy.
2018; 12(?):331-337. doi:
10.2147/dddt.s149119. [PMID: 29497279] - Harilal Patel, Prakash Patel, Nirav Modi, Shaival Shah, Ashok Ghoghari, Bhavesh Variya, Ritu Laddha, Dipesh Baradia, Nitin Dobaria, Pavak Mehta, Nuggehally R Srinivas. One should avoid retro-orbital pharmacokinetic sample collections for intranasal dosing in rats: Illustration of spurious pharmacokinetics generated for anti-migraine drugs zolmitriptan and eletriptan.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2017 Aug; 106(?):87-93. doi:
10.1016/j.ejps.2017.05.044. [PMID: 28549679] - Kentaro Tokuoka, Risa Takayanagi, Yuji Suzuki, Masayuki Watanabe, Yasuhisa Kitagawa, Yasuhiko Yamada. Theory-based analysis of clinical efficacy of triptans using receptor occupancy.
The journal of headache and pain.
2014 Dec; 15(?):85. doi:
10.1186/1129-2377-15-85. [PMID: 25488888] - Venkata Suresh Ponnuru, B R Challa, Ramarao Nadendla. Quantitative analysis of eletriptan in human plasma by HPLC-MS/MS and its application to pharmacokinetic study.
Analytical and bioanalytical chemistry.
2011 Nov; 401(8):2539-48. doi:
10.1007/s00216-011-5341-4. [PMID: 21892641] - Christopher M H Newman, Ian Starkey, Nigel Buller, Ricardo Seabra-Gomes, Simon Kirby, Jayasena Hettiarachchi, David Cumberland, William S Hillis. Effects of sumatriptan and eletriptan on diseased epicardial coronary arteries.
European journal of clinical pharmacology.
2005 Nov; 61(10):733-42. doi:
10.1007/s00228-005-0988-4. [PMID: 16151760] - Lars Edvinsson, Erik Uddman, Angelica Wackenfors, Anthony Davenport, Jenny Longmore, Malin Malmsjö. Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: relationship to clinical effect.
Clinical science (London, England : 1979).
2005 Sep; 109(3):335-42. doi:
10.1042/cs20050016. [PMID: 15853772] - Markus Färkkilä, Mikko Kallela. Eletriptan review.
Expert opinion on pharmacotherapy.
2005 Apr; 6(4):625-30. doi:
10.1517/14656566.6.4.625. [PMID: 15934888] - J Olesen, H C Diener, J Schoenen, J Hettiarachchi. No effect of eletriptan administration during the aura phase of migraine.
European journal of neurology.
2004 Oct; 11(10):671-7. doi:
10.1111/j.1468-1331.2004.00914.x. [PMID: 15469451] - Hisaka Igarashi. [Side effects of triptans].
No to shinkei = Brain and nerve.
2004 Sep; 56(9):754-9. doi:
". [PMID: 15552864] - J A Goldstein, K D Massey, S Kirby, M Gibson, J Hettiarachchi, A J Rankin, N C Jackson. Effect of high-dose intravenous eletriptan on coronary artery diameter.
Cephalalgia : an international journal of headache.
2004 Jul; 24(7):515-21. doi:
10.1111/j.1468-2982.2003.00713.x. [PMID: 15196292] - Ninan T Mathew, Jayasena Hettiarachchi, Jeffrey Alderman. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review.
Headache.
2003 Oct; 43(9):962-74. doi:
10.1046/j.1526-4610.2003.03188.x. [PMID: 14511273] - David C Evans, Desmond O'Connor, Brian G Lake, Raymond Evers, Christopher Allen, Richard Hargreaves. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein.
Drug metabolism and disposition: the biological fate of chemicals.
2003 Jul; 31(7):861-9. doi:
10.1124/dmd.31.7.861. [PMID: 12814962] - ". New medications show promise for migraine sufferers.
Dentistry today.
2002 Oct; 21(10):70. doi:
". [PMID: 12382492] - NULL. Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs.
Cephalalgia : an international journal of headache.
2002 Jul; 22(6):416-23. doi:
10.1046/j.1468-2982.2002.00372.x. [PMID: 12133040] - Ajit K Shah, Stephen C Harris, Catherine Greenhalgh, Joel Morganroth. The pharmacokinetics and safety of single escalating oral doses of eletriptan.
Journal of clinical pharmacology.
2002 May; 42(5):520-7. doi:
10.1177/00912700222011571. [PMID: 12017346] - K Ashley Milton, Nicholas R Scott, Michael J Allen, Samantha Abel, Vivienne C Jenkins, Gerry C James, David J Rance, Malcolm D Eve. Pharmacokinetics, pharmacodynamics, and safety of the 5-HT(1B/1D) agonist eletriptan following intravenous and oral administration.
Journal of clinical pharmacology.
2002 May; 42(5):528-39. doi:
10.1177/00912700222011580. [PMID: 12017347] - A K Shah, L Laboy-Goral, N Scott, T Morse, G Apseloff. Pharmacokinetics and safety of oral eletriptan during different phases of the menstrual cycle in healthy volunteers.
Journal of clinical pharmacology.
2001 Dec; 41(12):1339-44. doi:
10.1177/00912700122012922. [PMID: 11762561] - A MaassenVanDenBrink, R W van den Broek, R de Vries, A J Bogers, C J Avezaat, P R Saxena. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels.
Neurology.
2000 Nov; 55(10):1524-30. doi:
10.1212/wnl.55.10.1524. [PMID: 11094108] - D Deleu, Y Hanssens. Current and emerging second-generation triptans in acute migraine therapy: a comparative review.
Journal of clinical pharmacology.
2000 Jul; 40(7):687-700. doi:
10.1177/00912700022009431. [PMID: 10883409] - P Gupta, P Butler, N B Shepperson, A McHarg. The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT(1B/1D) receptor agonist.
European journal of pharmacology.
2000 Jun; 398(1):73-81. doi:
10.1016/s0014-2999(00)00240-5. [PMID: 10856450] - L Pichard-Garcia, R Hyland, J Baulieu, J M Fabre, A Milton, P Maurel. Human hepatocytes in primary culture predict lack of cytochrome P-450 3A4 induction by eletriptan in vivo.
Drug metabolism and disposition: the biological fate of chemicals.
2000 Jan; 28(1):51-7. doi:
NULL. [PMID: 10611140] - J D Cooper, D C Muirhead, J E Taylor. Determination of eletriptan in plasma and saliva using automated sequential trace enrichment of dialysate and high-performance liquid chromatography.
Journal of pharmaceutical and biomedical analysis.
1999 Dec; 21(4):787-96. doi:
10.1016/s0731-7085(99)00199-5. [PMID: 10701944] - Peter J Goadsby, Karen L Hoskin. Differential effects of low dose CP122,288 and eletriptan on fos expression due to stimulation of the superior sagittal sinus in cat.
Pain.
1999 Jul; 82(1):15-22. doi:
10.1016/s0304-3959(99)00025-1. [PMID: 10422655]